Thank you.
I'll say that the publication is a very good publication. It's not outstanding. It's a retrospective study and a lot more work is needed in this area. More work is being conducted by this group.
I think the evidence that is emerging from the study by CRISM on the 11 safe supply sites suggests that safe supply is beneficial to highly marginalized patients, assuming they also receive integrated services alongside the safer supply. The evidence there is actually quite strong. It's already been published, but it's qualitative in nature.
I think we are at a point now where safe supply, coupled with opioid agonist therapy, coupled with psychosocial services as a collective to reach people where they are, has a much greater chance of keeping them alive and keeping them out of emergency rooms by not having safe supply, by not having integrated services.
The evidence is growing, but it's—